日本儿童注意缺陷多动障碍药物处方：基于 2005 年至 2015 年医疗保险索赔数据的研究。
Drug Prescriptions for Children With ADHD in Japan: A Study Based on Health Insurance Claims Data Between 2005 and 2015.
机构信息
Tohoku University Hospital, Sendai, Japan.
Tohoku University Tohoku Medical Megabank Organization Sendai, Japan.
出版信息
J Atten Disord. 2020 Jan;24(2):175-191. doi: 10.1177/1087054719843179. Epub 2019 May 5.
The aim of this study is to investigate the trend of prescription drugs for children with ADHD in Japan. Using health insurance claims data of 3,672,951 people between January 2005 and December 2015, we investigated the trend of prescription drugs for 7,856 children with ADHD. After approval in 2007, the proportion of prescriptions for methylphenidate-osmotic-controlled release oral delivery system tablets was 31.4% in 2009 (adjusted odds ratio [AOR] = 2.72; 95% confidence interval [CI] = [2.12, 3.51]) and reached a plateau approximately after 2009 (AOR = 0.96; 95% CI = [0.94, 0.98]). The proportion of prescriptions for atomoxetine increased from 6.1% in 2008 to 21.8% in 2014 (AOR = 1.12; 95% CI = [1.13, 1.18]). The proportion of prescriptions for aripiprazole and ramelteon increased (all < .001). Prescriptions of drugs for children with ADHD have changed. We need to monitor the safety of ADHD medications among children with ADHD.
本研究旨在调查日本儿童注意缺陷多动障碍（ADHD）处方药物的趋势。我们使用了 2005 年 1 月至 2015 年 12 月期间 3672951 人的医疗保险索赔数据，调查了 7856 名 ADHD 儿童的处方药物趋势。在 2007 年获得批准后，2009 年哌醋甲酯-渗透控释口服传递系统片剂的处方比例为 31.4%（调整后的优势比 [AOR] = 2.72；95%置信区间 [CI] = [2.12, 3.51]），并在 2009 年左右达到平台期（AOR = 0.96；95% CI = [0.94, 0.98]）。阿托西汀的处方比例从 2008 年的 6.1%增加到 2014 年的 21.8%（AOR = 1.12；95% CI = [1.13, 1.18]）。阿立哌唑和雷美替胺的处方比例增加（均<.001）。儿童 ADHD 药物的处方已经发生变化。我们需要监测 ADHD 儿童 ADHD 药物的安全性。
Zotero 插件